Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombosis 2 Venous Thromboembolism 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Ischemic Stroke 1 Hypertension, Portal 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Cancer-associated Thrombosis 1 Adenocarcinoma 1

Interventions

Dexamethasone 111 Cyclophosphamide 99 Melphalan 91 Bortezomib 69 Peripheral Blood Stem Cell Transplantation 64 Lenalidomide 58 fludarabine phosphate 56 Busulfan 54 Filgrastim 50 Tacrolimus 38 Antilymphocyte Serum 38 Thalidomide 36 Radiotherapy 36 Mycophenolic Acid 33 fludarabine 28 Cyclosporine 26 Methotrexate 25 Etoposide 22 Calcium Dobesilate 22 Whole-Body Irradiation 21 Prednisone 21 Methylprednisolone 20 sargramostim 19 pomalidomide 19 Granulocyte Colony-Stimulating Factor 18 carfilzomib 16 daratumumab 15 Cord Blood Stem Cell Transplantation 15 Carmustine 14 Rituximab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Plasma Cell × Anticoagulants × Clear all

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡